Navigation Links
Webcast Alert: Akcea Therapeutics Conference Call
Date:5/28/2015

CARLSBAD, Calif., May 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:

Akcea Therapeutics WebcastWhen:

Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our website listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases.  These include ISIS-APOCIIIRx, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and partial lipodystrophy; ISIS-TTRRx, a drug Isis is developing with GSK to treat patients with the polyneuropathy and cardiomyopathy forms of TTR amyloidosis; and ISIS-SMNRx, a drug Isis is developing with Biogen to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis Pharmaceuticals, Isis' business, Akcea Therapeutics, the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-APOCIIIRx, ISIS-ANGPTL3Rx, ISIS-APO(a)Rx and their follow on drugs, and the discovery, development and therapeutic potential of these antisense drugs for the treatment of lipid disorders.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2014, and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Akcea Therapeutics™ is a trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO

 


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
2. Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast
3. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on May 13, 2015
4. Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders
5. Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
6. Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015
7. HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast
8. Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT
9. Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast
10. Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
11. AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 4th, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... LONE TREE, Colo. (PRWEB) , ... June 13, ... ... CO, is thrilled to open its doors to a wellness center dedicated to ... A. Atagi of Atagi Plastic Surgery & Skin Aesthetics, BESANA Health & Wellness ...
(Date:6/13/2019)... ... June 13, 2019 , ... IPVideo Corporation ... visual weapons detection systems, is proud to announce its verified integration with its ... verified technology partner IPVideo’s award-winning HALO sensor is now available on the Milestone ...
(Date:6/13/2019)... ... June 13, 2019 , ... The American Psychiatric Nurses Association announced ... current executive director Nicholas Croce Jr., MS. The search will be led by an ... past APNA Presidents, and Council and Chapter leaders. , The job description and more ...
Breaking Medicine Technology:
(Date:6/12/2019)... ... June 12, 2019 , ... ... relationships with caregivers and dementia patients to deteriorate. , Researchers from the ... a survey with professional caregivers who care for people who have dementia and ...
(Date:6/12/2019)... ... ... In September of 2018, NVNA and Hospice (NVNA) partnered with Health Recovery ... its full-scale launch in March, NVNA has expanded its program with HRS to provide ... has achieved an average all-cause hospital readmissions rate of 7.3% and has seen a ...
(Date:6/12/2019)... YORK (PRWEB) , ... June 12, 2019 , ... ... disability that significantly impacts their life, preventing them from participating in education or ... Project (ICP) will urge policymakers to recognize communication as a human right and ...
(Date:6/11/2019)... ... 11, 2019 , ... CareSet announced today that co-founder Ashish Patel has been ... through the TMCx Accelerator startup program and into expanded new offices located in Uptown, ... grown into a company of 18 and climbing. , “Ashish’s passion and work ...
(Date:6/6/2019)... ... June 06, 2019 , ... Dr. Eugene A. Isola III is an ... Hackensack Meridian Raritan Bay Medical Center. For Dr. Isola, dentistry is not just a ... Isola knows the importance of providing five-star services and treats his patients as if ...
Breaking Medicine News(10 mins):